TomoTherapy H Series System
September 25, 2013 – Accuray Inc. announced its momentum in gaining adoption for both the new CyberKnife M6 Series and TomoTherapy H Series Systems at the 55th Annual American Society for Radiation Oncology (ASTRO) Meeting taking place at the Georgia World Congress Center in Atlanta. Through presentations from leading radiation oncology practitioners and product demonstrations, attendees can gain further knowledge on the clinical capabilities of the CyberKnife M6 Series and TomoTherapy H Series Systems introduced at last year’s ASTRO meeting.
Adoption of Accuray’s latest advanced product platforms continues to grow, with many cancer centers in the United States and in Europe already investing in the technology. U.S. centers include the University of Pittsburgh Medical Center in Pennsylvania, Tulsa Cancer Institute of Oklahoma, Lancaster General Health in Pennsylvania, Spokane CyberKnife & Radiation Oncology Center in Washington and University of Arkansas Medical Sciences in Little Rock. Centers in Europe and Asia include, the European CyberKnife Center Munich-Grosshadern (ECZM) in Munich, Germany, Heidelberg University Hospital in Germany, Erasmus Medical Center (MC), in Rotterdam, the Netherlands, the Centre Oscar Lambretin Lille, France and The Severance Hospital, Yonsei University Healthcare System in Seoul, Korea.
These institutions have successfully implemented the new CyberKnife and TomoTherapy Systems and are experiencing significant benefits, including reduced treatment times, improved treatment plan quality, expanded patient treatment options for the CyberKnife M6 System, and reduced treatment planning time with the TomoHDA System.
“We have seen firsthand that the non-coplanar beam geometry of the CyberKnife M6 System allows us to create high-quality, high-dose distributions that can be delivered with extreme accuracy over a minimum number of treatments allowing us to minimize side effects and preserve our patients’ quality of life,” said Jeffrey S. Eshleman, M.D., director of radiation oncology, Ann B. Barshinger Cancer Institute of Lancaster General Health in Pennsylvania. “We are focused on providing the most effective and efficient SRS/SBRT treatment option and the CyberKnife System has excelled in its ability to track and treat moving targets while sparing nearby critical structures and healthy tissue.”
“In its first three months of clinical use at our center, the TomoHDA System has proven to be a versatile and efficient addition to our department,” said Prof. Eric Lartigau, M.D., Ph.D., Centre Oscar Lambret, Lille, France. “The system allows rapid treatment planning and high-precision dose delivery, a combination of features that lends itself well to breast cancer cases and helps improve overall quality, patient throughput and workflow for the department.”
“In an effort to enhance the capabilities of the TomoTherapy and CyberKnife Systems, our guiding mission is always to provide patients with the best possible treatment outcomes,” said Joshua H. Levine, president and chief executive officer of Accuray. “The feedback we have received from leading radiation oncology practitioners validates the decision to further invest in our unique product offerings. We look forward to our invaluable collaborators informing colleagues of their experiences and learnings to-date at this year’s ASTRO meeting.”
For more information: www.accuray.com
April 25, 2024 
